Yamazaki, Hirohito http://orcid.org/0000-0003-3018-2098
Ohta, Kensuke
Iida, Hiroatsu
Imada, Kazunori
Obara, Naoshi
Tokumine, Yukihiro
Tomiyama, Yoshiaki
Usuki, Kensuke
Imajo, Kenji
Miyamura, Koichi
Sasaki, Osamu
Fanghong, Zhang
Hattori, Toshihiro
Tajima, Takeshi
Matsuda, Akira
Nakao, Shinji
Clinical trials referenced in this document:
Documents that mention this clinical trial
Hematologic recovery induced by eltrombopag in Japanese patients with aplastic anemia refractory or intolerant to immunosuppressive therapy
https://doi.org/10.1007/s12185-019-02683-1
Funding for this research was provided by:
Novartis
Article History
Received: 2 December 2018
Revised: 3 June 2019
Accepted: 4 June 2019
First Online: 10 June 2019
Compliance with ethical standards
:
: HY has received grant/personal fees/non-financial support from Novartis. KO has received personal fees from Takeda, Celgene, Janssen, Bristol-Meyers Squibb, Ono, and Novartis. KI have received personal fees from Novartis, Bristol-Meyers Squibb, Takeda, Celgene, Nippon Shinyaku, MSD, Chugai, and Sumitomo Dainippon. YT received personal fees Novartis, Kyowa Hakko Kirin, and Chugai and provided advisory role to Novartis and Sysmex. HI, KM, and NO have declared no conflict of interest. KU has received grants from Astellas, AbbVie, Alexion, Gilead Sciences, SimBio, Daiichi-Sankyo, Sumitomo Dainippon, and personal fees from Novartis. TH, TT, and ZF are employees of Novartis. AM received personal fees from GlaxoSmithKline and Novartis Pharma during the conduct of the study, grants, and personal fees from Chugai, Kyowa Hakko Kirin, Sumitomo Dainippon, Nippon Shinyaku, GlaxoSmithKline, Novartis, Celgene, Alexion, Sanofi and Beckman Coulter, Shire Japan KK, Astellas, Asahi Kasei, Eisai, Otsuka, Boehringer Ingelheim, MSD, Daiichi-Sankyo, Abbvie, and HUYA Bioscience. SN has received personal fees from Novartis and Alexion.